Literature DB >> 21402834

Comparable population pharmacokinetics and pharmacodynamic breakpoints of cefpirome in cystic fibrosis patients and healthy volunteers.

J B Bulitta1, M Kinzig, C B Landersdorfer, U Holzgrabe, U Stephan, F Sörgel.   

Abstract

Cystic fibrosis (CF) patients are often reported to have higher clearances and larger volumes of distribution per kilogram of total body weight (WT) for beta-lactams than healthy volunteers. As pharmacokinetic (PK) data on cefpirome from studies of CF patients are lacking, we systematically compared its population PK and pharmacodynamic breakpoints for CF patients and healthy volunteers of similar body size. Twelve adult CF patients (median lean body mass [LBM] = 45.7 kg) and 12 healthy volunteers (LBM = 50.0 kg) received a single 10-min intravenous infusion of 2 g cefpirome. Plasma and urine concentrations were determined by high-performance liquid chromatography (HPLC). Population PK and Monte Carlo simulations were performed using NONMEM and S-ADAPT and a duration of an unbound plasma concentration above the MIC ≥ 65% of the dosing interval as a pharmacodynamic target. Unscaled clearances for CF patients were similar to those seen with healthy volunteers, and the volume of distribution was 6% lower for CF patients. Linear scaling of total clearance by WT resulted in clearance that was 20% higher (P ≤ 0.001 [nonparametric bootstrap]) in CF patients. Allometric scaling by LBM explained the differences between the two subject groups with respect to average clearance and volume of distribution and reduced the unexplained between-subject variability of renal and nonrenal clearance by 10 to 14%. For the CF patients, robust (>90%) probabilities of target attainment (PTA) were achieved by the administration of a standard dose of 2 g/70 kg WT every 12 h (Q12h) given as 30-min infusions for MICs ≤ 1.5 mg/liter. As alternative dosage regimens, a 5-h infusion of 1.33 g/70 kg WT Q8h achieved robust PTAs for MICs ≤ 8 to 12 mg/liter and a continuous infusion of 4 g/day for MICs ≤ 12 mg/liter. Prolonged infusion of cefpirome is expected to be superior to short-term infusions for MICs between 2 and 12 mg/liter.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21402834      PMCID: PMC3101446          DOI: 10.1128/AAC.01484-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  59 in total

Review 1.  Pharmacokinetics and pharmacodynamics of antimicrobials.

Authors:  G L Drusano
Journal:  Clin Infect Dis       Date:  2007-07-15       Impact factor: 9.079

Review 2.  Drug disposition in cystic fibrosis.

Authors:  E Rey; J M Tréluyer; G Pons
Journal:  Clin Pharmacokinet       Date:  1998-10       Impact factor: 6.447

3.  [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (2004)].

Authors:  Hajime Goto; Hideki Takeda; Shin Kawai; Takashi Watanabe; Mitsuhiro Okazaki; Kaoru Shimada; Kunio Nakano; Hiroshi Yokouchi; Hideo Ikemoto; Takeshi Mori; Jun Igari; Toyoko Oguri; Makoto Yamamoto; Hiroshi Inoue; Toshihide Nakadate; Akira Suwabe; Yugo Ashino; Fumitake Gejyo; Masahiko Okada; Nobuki Aoki; Nobuko Kitamura; Yasutoshi Suzuki; Yasuo Karasawa; Koichiro Kudo; Nobuyuki Kobayashi; Tsukasa Tanaka; Midori Sumitomo; Toshiharu Matsushima; Mikio Oka; Yoshihiko Niki; Moritaka Suga; Masakazu Tosaka; Shigeru Kohno; Yoichi Hirakata; Akira Kondou; Junichi Matsuda; Michiko Nakano; Masaru Nasu; Kazufumi Hiramatsu; Satoru Oikawa
Journal:  Jpn J Antibiot       Date:  2006-10

4.  Pharmacokinetics in vivo and pharmacodynamics ex vivo/in vitro of meropenem and cefpirome in the Yucatan micropig model: continuous infusion versus intermittent injection.

Authors:  Hassan Elkhaïli; Jean-Daniel Peter; Davide Pompei; Dominique Levless-Than-Or-Eq Slanteque; Laurence Linger; Yves Salmon; Julie Salmon; Henri Monteil
Journal:  Clin Microbiol Infect       Date:  1998-01       Impact factor: 8.067

5.  Multicentre study of the in vitro activity of cefepime, a broad-spectrum cephalosporin, compared to other broad-spectrum agents.

Authors:  J M Bell; J D Turnidge
Journal:  Pathology       Date:  2001-02       Impact factor: 5.306

6.  Dose linearity testing of intravenous cefpirome (HR 810), a novel cephalosporin derivate.

Authors:  L Maass; V Malerczyk; M Verho; P Hajdú; K Seeger; N Klesel
Journal:  Infection       Date:  1987 May-Jun       Impact factor: 3.553

7.  Evaluation of the in vitro activity of six broad-spectrum beta-lactam antimicrobial agents tested against recent clinical isolates from India: a survey of ten medical center laboratories.

Authors:  Dilip Mathai; Paul R Rhomberg; Douglas J Biedenbach; Ronald N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2002-12       Impact factor: 2.803

8.  Comparative antimicrobial activity of FK037, cefpirome, ceftazidime and cefepime against aminoglycoside-sensitive and aminoglycoside-resistant Pseudomonas aeruginosa and Pseudomonas spp.

Authors:  A L Baltch; R P Smith; W Ritz
Journal:  Chemotherapy       Date:  1994       Impact factor: 2.544

9.  [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (2003). III. Secular changes in susceptibility].

Authors:  Yoshiaki Kumamoto; Taiji Tsukamoto; Masanori Matsukawa; Yasuharu Kunishima; Kiyoaki Watanabe; Yoshio Kobayashi; Hiroshi Uchida; Seiji Matsuda; Takaoki Hirose; Shinichi Sato; Shiro Shigeta; Makoto Fujime; Kazuhiko Fujita; Osamu Yamaguti; Kei Ishibashi; Jun Igari; Tatsuo Suzutani; Toyoko Oguri; Hiroshi Yoshida; Yuuji Imafuku; Keizo Yamaguchi; Nobuhiko Furuya; Masaru Murai; Takashi Deguchi; Satoshi Ishihara; Hiroshi Ooe; Tetsuro Matsumoto; Koichi Takahashi; Mineko Nishikawa; Sejij Naito; Toshihisa Egashira; Takatoshi Konishi; Toshitsugu Oka; Masaya Kitamura; Shigeru Kohno; Yoshinori Fukuhara; Yoichi Hirakata; Akira Kondo; Junichi Matsuda; Michiko Nakano; Sadao Kamidono; Yumiko Suzuki; Soichi Arakawa; Hiromi Kumon; Koichi Monden
Journal:  Jpn J Antibiot       Date:  2005-12

10.  Comparison of the pharmacokinetics and pharmacodynamic profile of carumonam in cystic fibrosis patients and healthy volunteers.

Authors:  Jürgen B Bulitta; Stephen B Duffull; Cornelia B Landersdorfer; Martina Kinzig; Ulrike Holzgrabe; Ulrich Stephan; George L Drusano; Fritz Sörgel
Journal:  Diagn Microbiol Infect Dis       Date:  2009-10       Impact factor: 2.803

View more
  5 in total

1.  A mouse model to evaluate the impact of species, sex, and lipid load on lymphatic drug transport.

Authors:  Natalie L Trevaskis; Suzanne M Caliph; Gary Nguyen; Patrick Tso; William N Charman; Christopher J H Porter
Journal:  Pharm Res       Date:  2013-02-21       Impact factor: 4.200

2.  Antibiotics in Adult Cystic Fibrosis Patients: A Review of Population Pharmacokinetic Analyses.

Authors:  Mehdi El Hassani; Jean-Alexandre Caissy; Amélie Marsot
Journal:  Clin Pharmacokinet       Date:  2021-01-15       Impact factor: 6.447

3.  Population pharmacokinetics of piperacillin at two dose levels: influence of nonlinear pharmacokinetics on the pharmacodynamic profile.

Authors:  Cornelia B Landersdorfer; Jurgen B Bulitta; Carl M J Kirkpatrick; Martina Kinzig; Ulrike Holzgrabe; George L Drusano; Ulrich Stephan; Fritz Sörgel
Journal:  Antimicrob Agents Chemother       Date:  2012-08-20       Impact factor: 5.191

4.  Optimal dosing of miltefosine in children and adults with visceral leishmaniasis.

Authors:  Thomas P C Dorlo; Alwin D R Huitema; Jos H Beijnen; Peter J de Vries
Journal:  Antimicrob Agents Chemother       Date:  2012-05-14       Impact factor: 5.191

Review 5.  Four Decades of β-Lactam Antibiotic Pharmacokinetics in Cystic Fibrosis.

Authors:  Jürgen B Bulitta; Yuanyuan Jiao; Stefanie K Drescher; Antonio Oliver; Arnold Louie; Bartolome Moya; Xun Tao; Mathias Wittau; Brian T Tsuji; Alexandre P Zavascki; Beom Soo Shin; George L Drusano; Fritz Sörgel; Cornelia B Landersdorfer
Journal:  Clin Pharmacokinet       Date:  2019-02       Impact factor: 6.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.